Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06469281 · ClinicalTrials.gov registry record · Phase 1
A Study to Learn if 27T51, a Mucin-16 (MUC16) Protein Targeting Immune Cell Therapy, Administered Alone or in Combination is Safe and How Well it Works for Adult Participants With Recurrent or Treatment Resistant Ovarian Cancers
A Phase 1 study of Fallopian Tube Cancer and Epithelial Ovarian Cancer, sponsored by Regeneron Pharmaceuticals.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 90
- Enrollment target
- 5
- Study locations
NCT06469281: Recruiting Phase 1 study of Fallopian Tube Cancer and Epithelial Ovarian Cancer, sponsored by Regeneron Pharmaceuticals.
NCT06469281 is a Phase 1 study of Fallopian Tube Cancer and Epithelial Ovarian Cancer that is actively recruiting participants, run by Regeneron Pharmaceuticals. The registered enrollment target is 90 participants, below the 255-participant average among 85 other Fallopian Tube Cancer trials with a reported enrollment target (65% lower). The trial reports 5 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06469281, a Phase 1 study of Fallopian Tube Cancer and Epithelial Ovarian Cancer, is actively recruiting participants, sponsored by Regeneron Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 90 participants
- Enrollment target
- 5
- Study locations
Study Summary
This study is researching an experimental CAR T cell therapy called 27T51, referred to as study drug. The study drug is a MUC16 targeting immune cell therapy focused on adult female participants with recurrent or difficult to treat epithelial ovarian, primary peritoneal or fallopian tube cancer. This study has two (2) major parts: Phase 1a Dose Escalation and Phase 1b Dose Expansion. The aim of the dose escalation part will be to test the safety of 27T51 in a small number of participants to find the highest dose given to humans without unacceptable side effects. The aim of the dose expansion part will be to test 27T51 at the established dose level(s) from the dose escalation part and may include other medications given in combination with 27T51. Information collected from this study will help researchers understand more fully whether this immune cell therapy, also known as CAR T cell therapy, can be safely used to treat solid tumors such as ovarian cancer.
Primary Outcome
Part 1a
Conditions Studied
Interventions
- DRUG Bevacizumab
- DRUG Cemiplimab
- OTHER 27T51
Study Locations (5)
Massachusetts
- Massachusetts General Hospital - Boston
New Jersey
- John Theurer Cancer Center Hackensack University Medical Center - Hackensack
New York
- Roswell Park Cancer Institute - Buffalo
Pennsylvania
- UPMC Hillman Cancer Center - Pittsburgh
Utah
- LDS Hospital - Salt Lake City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2024-08-06 |
| Est. Completion | 2030-05-27 |
| Phase | Phase 1 |
What NCT06469281 shows while recruiting
NCT06469281 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 90 participants, a relatively small participant target, below the 255-participant average among 85 other Fallopian Tube Cancer trials with a reported enrollment target (65% lower).
The record links to 3 conditions, with Fallopian Tube Cancer appearing as the primary indexed condition, and to 3 interventions - of which Bevacizumab is the first listed.
NCT06469281 lists 5 locations in 5 states (Massachusetts, New Jersey, New York).
Frequently Asked Questions
What is clinical trial NCT06469281 about?
NCT06469281 is a clinical study titled "A Study to Learn if 27T51, a Mucin-16 (MUC16) Protein Targeting Immune Cell Therapy, Administered Alone or in Combination is Safe and How Well it Works for Adult Participants With Recurrent or Treatment Resistant Ovarian Cancers". This study is researching an experimental CAR T cell therapy called 27T51, referred to as study drug. The study drug is a MUC16 targeting immune cell therapy focused on adult female participants with recurrent or difficult to treat epithelial ovarian, primary peritoneal or fallopian tube cancer. Th...
What is the current status of trial NCT06469281?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 90 participants. The study started on 2024-08-06. Estimated completion is 2030-05-27.
What conditions does trial NCT06469281 study?
This clinical trial studies the following conditions: Fallopian Tube Cancer, Epithelial Ovarian Cancer, Primary Peritoneal Carcinoma.
What interventions are being tested in trial NCT06469281?
The interventions under investigation include: Bevacizumab (DRUG), Cemiplimab (DRUG), 27T51 (OTHER).
Who is sponsoring clinical trial NCT06469281?
This trial is sponsored by Regeneron Pharmaceuticals, which has 280 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06469281 being conducted?
This trial has 5 study locations across Massachusetts, New Jersey, New York, Pennsylvania, Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Fallopian Tube Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06469281's enrollment target sits among peer trials
90 38th of 85 higher than 48 of 85 other Fallopian Tube Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Fallopian Tube Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study of AVZO-021 in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Phase II IMNN-001 (Also Known as GEN-1) on SLL With BEV and NACT, Newly Diagnosed Advanced Ovarian, Fallopian Tube or Primary Peritoneal Cancer
RECRUITING · Phase 1
-
Cirtuvivint/Olaparib in Breast Cancer Susceptibility Gene/Homologous Recombination Deficiency Platinum Resistant Ovarian Cancer
RECRUITING · Phase 1
-
A Study of ZN-c3 in Patients With Ovarian Cancer
RECRUITING · Phase 1
-
A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given With Either Cemiplimab, or Cemiplimab + Fianlimab, or Ubamatamab
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02521311 · 90 participants · Phase 2
Assessment of Clemastine Fumarate as a Remyelinating Agent in Acute Optic Neuritis (ReCOVER)
- NCT02939573 · 90 participants · Phase 2
A Randomized Multicenter Study for Isolated Skin Vasculitis
- NCT03128879 · 90 participants · Phase 2
Venetoclax With Ibrutinib or Acalabrutinib in Pts. With High-risk CLL
- NCT03184038 · 90 participants · NA
Neurocognition in Patients With Multiple Brain Metastases Treated With Radiosurgery
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI